SERA PROGNOSTICS APPOINTS SCOTT GLEASON CHIEF FINANCIAL OFFICER

Sera Prognostics (SERA) reported Q2 2026 revenue of $30,000, up from $17,000 last year, with a net loss of $9.1 million. The company exceeded its payer engagement goal, reaching over 20 states, and launched four commercial partnership programs. Clinical data showed a 22% reduction in NICU admissions and a 30% reduction in neonatal morbidity among first-time mothers. Management expects cash to fund operations through 2029.

Sera Prognostics (Nasdaq: SERA) reported Q2 2026 revenue of $30,000 versus $17,000 in Q2 2025, with operating expenses of $10.0 million and a net loss of $9.1 million. The company said Illinois Medicaid coverage for PreTRM proteomic tests expanded, it launched a fourth payer partnership program, and PRIME trial data showed reduced NICU admissions in first-time mothers. Cash was about $80.3 million.

SERA PROGNOSTICS, INC. (SERA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SERA PROGNOSTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS Salt Lake City – August 12, 2026 – Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information t

Sera Prognostics (Nasdaq: SERA) reported a PRIME trial subgroup analysis in first-time pregnancies (n=1,783). According to the company, PreTRM Test-guided care reduced NICU admissions by 22% versus routine care and lowered severe composite morbidity (6.4% vs 9.1%). The study also cited 28 screenings to prevent one NICU admission.

INNIO (INIO) received a 450-MW order from an unnamed US energy company for gas engines, with delivery by 2028. The order is part of a growing backlog, with Q2 orders up 316% YoY to $2.3B. Revenue rose 42% to $937.7M, but margins fell. INNIO guides to $3.8B-$3.9B in fiscal 2026 sales. 55 hedge funds now hold INIO, while 15.73% of float is sold short.

Jones Lang LaSalle (JLL) appointed Paul Morgan as Chief Operating Officer, a new role aimed at consolidating global operations. Q2 revenue rose 11% to $6.9B, with adjusted EBITDA up 32%. Management raised full-year EPS guidance, but some segments showed slower growth. The stock trades at 10.41x forward earnings, with low short interest.